Pharmacological Management of Diabetic Nephropathy.

Abstract:

INTRODUCTION:Diabetes mellitus (DM) is one of the most common diseases worldwide. Its adverse effects on several body organs, have made treatment of DM a priority. One of the most serious complications of DM is diabetic nephropathy (DN). OBJECTIVE:The aim of this review is to critically discuss available data on the pharmacological management of DN. METHODS:A comprehensive review of the literature was performed to identify studies assessing the impact of several drug classes on DN. RESULTS:Several studies have been conducted in order to find a novel and effective treatment of DN. So far, the cornerstone therapy of DN consists of renin-angiotensin system (RAS) inhibitors, agents that decrease the synthesis of intrarenal angiotensin II or block its receptors. Their antiproteinuric and antihypertensive effects can not only decelerate the progress of DN but prevent its onset as well. Novel antidiabetic drugs, such as sodium-glucose cotransporter 2 inhibitors (SGLT-2i) and glucagon-like peptide- 1 receptor agonists (GLP-1 RA), are promising agents in the therapy of DN, due to their positive effect on renal and cardiovascular adverse events. From lipid-lowering agents, atorvastatin improves DN up to stage 3 and substantially reduces CVD. CONCLUSION:RAS inhibitors, SGLT-2i and GLP-1 agonists were found to be beneficial for the treatment of DN. Larger renal trials are needed in order to incorporate these drugs into the first line treatment of DN.

journal_name

Curr Vasc Pharmacol

authors

Papademetriou V,Alataki S,Stavropoulos K,Papadopoulos C,Bakogiannis K,Tsioufis K

doi

10.2174/1570161117666190405164749

subject

Has Abstract

pub_date

2020-01-01 00:00:00

pages

139-147

issue

2

eissn

1570-1611

issn

1875-6212

pii

CVP-EPUB-97858

journal_volume

18

pub_type

杂志文章,评审
  • Aldosterone, from (patho)physiology to treatment in cardiovascular and renal damage.

    abstract::Aldosterone, a steroid hormone with mineralocorticoid activity, is far more than merely a salt-and-water hormone. Aldosterone has a number of non-classical, mineralocorticoid receptor (MR)-mediated actions, including tissue remodeling, modulation of vascular tone and stimulating inflammation and fibrosis, which may fu...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/157016111796642689

    authors: Waanders F,de Vries LV,van Goor H,Hillebrands JL,Laverman GD,Bakker SJ,Navis G

    更新日期:2011-09-01 00:00:00

  • Paget's Disease of Bone and Cardiovascular Risk: a Pilot Study.

    abstract:BACKGROUND:The association between Paget's disease of bone (PDB) and increased cardiovascular (CV) risk has been suggested, but the literature is conflicting. OBJECTIVE:Our study aimed to evaluate two markers of CV risk [common carotid artery intima-media thickness (cIMT) and the aortic pulse wave velocity (PWV)] in p...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章

    doi:10.2174/1389450121666200609151555

    authors: Gaudio A,Zanoli L,Xourafa A,Rapisarda R,Catalano A,Signorelli SS,Castellino P

    更新日期:2020-06-09 00:00:00

  • Clopidogrel Hypersensitivity: Pathogenesis, Presentation and Diagnosis.

    abstract::This paper provides an overview of the pathogenesis, presentation and diagnosis of clopidogrel hypersensitivity. The majority of clopidogrel hypersensitivity cases are due to a T cell mediated Gell and Coombs Type IV reaction. History, histology, and patch testing have shown consistency with a T cell mediated mechanis...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/1570161116666181031143628

    authors: Ford MK,Cohn JR

    更新日期:2019-01-01 00:00:00

  • Clinical management of the cardiovascular failure in sepsis.

    abstract::Cardiovascular failure in sepsis involves a combination of hypovolemia, decreased vascular tone, myocardial depression and microcirculatory alterations. Fluids represent the first line therapeutic intervention, with controversy regarding the type of fluid. Recent data indicate that albumin is safe and might even be be...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: De Backer D,Scolletta S

    更新日期:2013-03-01 00:00:00

  • Visfatin/PBEF and atherosclerosis-related diseases.

    abstract::Visfatin is highly expressed in adipose tissue (mainly by the stromal cells), but it is also ubiquitously present in most tissues. Visfatin, which plays a role in nicotinamide adenine dinucleotide (NAD) biosynthesis, has been implicated in inflammatory states. Controversial results exist about the expression, circulat...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/157016110790226679

    authors: Filippatos TD,Randeva HS,Derdemezis CS,Elisaf MS,Mikhailidis DP

    更新日期:2010-01-01 00:00:00

  • New insights into the mechanisms underlying vascular and cardiac effects of urocortin.

    abstract::Urocortin comprises a group of endogenously produced peptide hormones that belong to the corticotropinreleasing factor (CRF) family with promising future as potential drugs for the treatment of heart disease. Members of the urocortin family are known to act as potent regulators of cardiac and vascular functions, throu...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/1570161111311040009

    authors: Díaz I,Smani T

    更新日期:2013-07-01 00:00:00

  • Regulation of blood flow by prostaglandins.

    abstract::Prostaglandins (PGs) belong to the family of prostanoids together with thromboxanes and are produced mainly from arachadonic acid by the enzyme cyclooxygenase. PGs are known to stimulate platelet aggregation, mediate inflammation and edema, play a role in bone metabolism and in biological adaptation of connective tiss...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/1570161043476410

    authors: Boushel R,Langberg H,Risum N,Kjaer M

    更新日期:2004-04-01 00:00:00

  • Renalase is removed by kidneys and during dialysis - excess related to CKD complications?

    abstract:BACKGROUND:The most common complications of chronic kidney disease (CKD) are hypertension and cardiovascular (CV) disorders. Renalase is produced and released by the kidney and also cardiomyocytes. Renalase deficiency was claimed to be responsible for hypertension and CV complication in CKD. There are contradictory dat...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章

    doi:10.2174/1570161113666141217141805

    authors: Malyszko J,Koc-Zorawska E,Zorawski M,Kozminski P,Zbroch E,Rysz J,Banach M,Malyszko JS

    更新日期:2015-01-01 00:00:00

  • Endothelial dysfunction in cardiac allograft vasculopathy: potential pharmacological interventions.

    abstract::Nowadays long-term outcome of heart transplantation is limited by a peculiar type of coronary atherosclerosis, known as cardiac allograft vasculopathy (CAV). Although the exact pathogenesis of CAV remains unclear, emerging evidence indicates that the endothelium plays a significant role in the onset and progression of...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/157016110790886992

    authors: Osto E,Tona F,De Bon E,Iliceto S,Cella G

    更新日期:2010-03-01 00:00:00

  • Editorial: aliskiren/amlodipine single-pill combinations: more evidence in favour of combination formulations for the treatment of hypertension.

    abstract::In this issue of Curr Vasc Pharmacol, Pfeiffer et al. [1] and Glorioso et al. [2] report the efficacy and tolerability of aliskiren/amlodipine single-pill combinations (SPCs) in patients with inadequate blood pressure (BP) response to amlodipine or aliskiren monotherapy, respectively. ...

    journal_title:Current vascular pharmacology

    pub_type: 评论,社论

    doi:10.2174/157016112803520783

    authors: Katsiki N,Athyros VG,Mikhailidis DP,Karagiannis A

    更新日期:2012-11-01 00:00:00

  • Natural phenolic compounds as cardiovascular therapeutics: potential role of their antiinflammatory effects.

    abstract::A number of epidemiological studies have shown that diets rich in plant-derived phenolic compounds reduce the risk of coronary heart disease. The chronic antioxidant and hypolipidemic activities of these compounds have important roles in prevention of lipoprotein oxidation and atherosclerotic lesion development. In re...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/1570161033476736

    authors: Jiang F,Dusting GJ

    更新日期:2003-06-01 00:00:00

  • Statins: Are they really all the same?

    abstract:: ...

    journal_title:Current vascular pharmacology

    pub_type: 社论

    doi:10.2174/1570161116666180713120217

    authors: Cortese F

    更新日期:2019-01-01 00:00:00

  • Pleiotropic effects of ARB in vascular metabolism--focusing on atherosclerosis-based cardiovascular disease.

    abstract::The renin-angiotensin system (RAS) plays an essential role in fluid and electrolyte homeostasis and the regulation of vascular tone; however, dysregulation and over-activation of the RAS lead to the pathogenesis of various cardiovascular diseases. The RAS is closely associated with NADPH oxidase, a major enzymatic sou...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/157016111794519273

    authors: Honjo T,Yamaoka-Tojo M,Inoue N

    更新日期:2011-03-01 00:00:00

  • Cardiovascular effects of endogenous estrogen and hormone therapy.

    abstract::The incidence of cardiovascular disease is low in healthy premenopausal women and increases with age especially after the menopause; this difference has been attributed to the loss of endogenous estrogen. Atherosclerosis is a chronic inflammatory condition of the vascular wall that may result in an acute clinical even...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/157016110790886974

    authors: Bechlioulis A,Naka KK,Calis KA,Makrigiannakis A,Michalis L,Kalantaridou SN

    更新日期:2010-03-01 00:00:00

  • New Insights into the Role of FGF-23 and Klotho in Cardiovascular Disease in Chronic Kidney Disease Patients.

    abstract::Alterations of fibroblast growth factor 23 (FGF-23) and Klotho levels are considered to be the earliest biochemical abnormality of chronic kidney disease - mineral and bone disease (CKDMBD) syndrome. Moreover, emerging data suggests that the dysregulated FGF-23 and Klotho axis has many effects on the cardiovascular (C...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章

    doi:10.2174/1570161118666200420102100

    authors: Memmos E,Papagianni A

    更新日期:2021-01-01 00:00:00

  • Prevalence, diagnosis and treatment with 3 different statins of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis in military personnel. Do genetics play a role?

    abstract:BACKGROUND:Non-alcoholic fatty liver disease (NAFLD) and its severe form, non-alcoholic steatohepatitis (NASH), are major health problems worldwide. Genetics may play a role in the pathogenesis of NAFLD/NASH. AIM:To investigate the prevalence of NAFLD/NASH in 5,400 military personnel and evaluate the effect of treatme...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章

    doi:10.2174/1570161118666201015152921

    authors: Sfikas G,Psallas M,Koumaras C,Imprialos K,Perdikakis E,Doumas M,Giouleme O,Karagiannis A,Athyros VG

    更新日期:2020-10-15 00:00:00

  • Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Narrative Review.

    abstract::Postprandial hypertriglyceridaemia, defined as an increase in plasma triglyceride-containing lipoproteins following a fat meal, is a potential risk predictor of atherosclerotic cardiovascular disease and other chronic diseases. Several non-modifiable factors (genetics, age, sex and menopausal status) and lifestyle fac...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,实务指引,评审

    doi:10.2174/1570161117666190503123911

    authors: Kolovou GD,Watts GF,Mikhailidis DP,Pérez-Martínez P,Mora S,Bilianou H,Panotopoulos G,Katsiki N,Ooi TC,Lopez-Miranda J,Tybjærg-Hansen A,Tentolouris N,Nordestgaard BG

    更新日期:2019-01-01 00:00:00

  • Use of Non-Selective Non-Steroidal Anti-Inflammatory Drugs in Relation to Cardiovascular Events. A Systematic Pharmacoepidemiological Review.

    abstract:BACKGROUND:Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used, having numerous indications. However, despite their therapeutic role, they are associated with serious cardiovascular (CV) adverse events. Objectives-Methods: This review comprising recent observational studies and metaanalyses over the past few...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/1570161114666160728093323

    authors: Kontogiorgis C,Valikeserlis I,Hadjipavlou-Litina D,Nena E,Constantinidis TC

    更新日期:2016-01-01 00:00:00

  • What is the Role for Glycoprotein IIb/IIIa Inhibitor Use in the Catheterization Laboratory in the Current Era?

    abstract:BACKGROUND:In the era of dual antiplatelet therapy of aspirin and clopidogrel and systematic stent implantation, Glycoprotein IIb/IIIa Inhibitors (GPI), including abciximab, eptifibatide and tirofiban, proved beneficial in improving early outcome of Percutaneous Coronary Intervention (PCI), especially in higher risk cl...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/1570161116666180117102422

    authors: Rubboli A,Patti G

    更新日期:2018-01-01 00:00:00

  • Epigenetics: new concepts of old phenomena in vascular physiology.

    abstract::The hypothesis of 'Developmental Origins of Health and Disease' (DOHaD) relies on the presence of mechanisms sensing and signalling a diversity of stimuli during fetal development. The mechanisms that have been broadly suggested to be involved in these processes are the epigenetic modifications that could 'record' per...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/157016109789043883

    authors: Krause B,Sobrevia L,Casanello P

    更新日期:2009-10-01 00:00:00

  • Vitamin D is Related to Markers of Vulnerable Plaque in Acute Myocardial Infarction.

    abstract:BACKGROUND:Vitamin D is a fat soluble vitamin involved in calcium and bone metabolism; recently its deficiency has been related to cardiovascular disease. In cardiac tissue, vitamin D suppresses metalloproteinases (MMPs) expression, enzymes directly associated with vulnerable plaque. OBJECTIVE:To investigate whether t...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章

    doi:10.2174/1570161115666170609102506

    authors: Machulsky NF,Barchuk M,Gagliardi J,Gonzalez D,Lombardo M,Escudero AG,Gigena G,Blanco F,Schreier L,Fabre B,Berg G

    更新日期:2018-01-01 00:00:00

  • Current and Potential Future Pharmacological Approaches for Non- Alcoholic Fatty Liver Disease.

    abstract:BACKGROUND:Non-alcoholic fatty liver disease (NAFLD) affects a large proportion of the general population. The disease ranges from simple steatosis, to non-alcoholic steatohepatitis (NASH), cirrhosis and even hepatocellular carcinoma. Several drugs are used in daily clinical practice to manage the disease. However, dat...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/1570161115666170621083744

    authors: Imprialos K,Stavropoulos K,Bouloukou S,Kerpiniotis G,Karagiannis A,Doumas M

    更新日期:2018-01-01 00:00:00

  • Glycosaminoglycan sulodexide inhibition of MMP-9 gelatinase secretion and activity: possible pharmacological role against collagen degradation in vascular chronic diseases.

    abstract::We evaluated the effects of the glycosaminoglycan sulodexide (SDX; antithrombotic/profibrinolytic drug) on the activity and release of matrix metalloproteinases (MMPs) in human blood. This was a prospective non-randomized study, analyzing by zymography and ELISA the in vitro effects of SDX on pro-enzyme, complexed, an...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章

    doi:10.2174/1570161111311030010

    authors: Mannello F,Medda V,Ligi D,Raffetto JD

    更新日期:2013-05-01 00:00:00

  • Recommendations for severe hypertriglyceridemia treatment, are there new strategies?

    abstract::This review considers drug combinations and newer treatment strategies for patients with severe hypertriglyceridemia. Hypertriglyceridemia is associated with an atherogenic metabolic profile and in most studies with increased cardiovascular disease risk. Patients with severe hypertriglyceridemia also have increased in...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/15701611113119990133

    authors: Filippatos TD,Elisaf MS

    更新日期:2014-01-01 00:00:00

  • Oxidative-nitrosative stress in hypertension.

    abstract::Reactive oxygen species (ROS) are important signaling molecules in the vasculature. However, when there is imbalance between their occurrence and antioxidant defense mechanisms, ROS can contribute to the vascular abnormalities that lead to hypertension. Evidence accumulated in the last decade strongly supports the not...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/1570161054368643

    authors: Escobales N,Crespo MJ

    更新日期:2005-07-01 00:00:00

  • Platelets and platelet interaction with progenitor cells in vascular homeostasis and inflammation.

    abstract::Platelet adhesion on vascular wall is the first step following vascular injury. Differential platelet secretion supports angiogenesis and vascular homeostasis. Progenitor cells are pluripotent cells responsible for tissue regeneration and wound healing. Upon ischemia bone marrow-derived progenitor cells are mobilized ...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/157016112801784486

    authors: Sopova K,Tatsidou P,Stellos K

    更新日期:2012-09-01 00:00:00

  • Therapeutic potential of high mobility group box-1 in ischemic injury and tissue regeneration.

    abstract::High-mobility group box-1 (HMGB1) is a nuclear protein that acts as a cytokine when released into the extracellular milieu by necrotic and inflammatory cells, and is involved in inflammatory responses and tissue repair. This protein is released passively during cellular necrosis by almost all cells that have a nucleus...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/157016111797484125

    authors: Biscetti F,Ghirlanda G,Flex A

    更新日期:2011-11-01 00:00:00

  • Hypertension: quo vadis?

    abstract::High blood pressure (BP) along with smoking habit and lipid disorders are the most important and modifiable risk factors for cardiovascular diseases. However, the prevalence of high BP has grown progressively over time with a progressive increase not only in the absolute number of patients but in the proportion of tho...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/157016112803520927

    authors: Borghi C

    更新日期:2012-11-01 00:00:00

  • Effects of kallistatin on oxidative stress and inflammation on renal ischemia-reperfusion injury in mice.

    abstract:BACKGROUND:Kallistatin (KS) is a serine proteinase. The result of KS on 'Renal Ischemia- Reperfusion Injury' (IRI) has not clearly been researched. In this study, investigative research has been conducted to draw results on the administration of human KS on kidney response conducted within a mouse model of IRI. MATERI...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章

    doi:10.2174/1570161113666150204142716

    authors: Zhou S,Sun Y,Zhuang Y,Zhao W,Chen Y,Jiang B,Guo C,Zhang Z,Peng H,Chen Y

    更新日期:2015-01-01 00:00:00

  • The saphenous vein as a bypass conduit: the potential role of vascular nerves in graft performance.

    abstract::The saphenous vein is the most commonly used conduit in patients undergoing coronary artery bypass surgery. However, a high proportion of vein grafts occlude within the first year and over 50% patients require further grafting within 10 years. Using conventional harvesting techniques the saphenous vein is damaged due ...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/157016109787354132

    authors: Dashwood MR,Loesch A

    更新日期:2009-01-01 00:00:00